Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma

Paul D. Brown, Ashley W. Jensen, Sara J. Felten, Karla V. Ballman, Paul L. Schaefer, Kurt A. Jaeckle, Jane H. Cerhan, Jan C. Buckner

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed. Patients and Methods: We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time. Results: The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression. Conclusion: The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.

Original languageEnglish (US)
Pages (from-to)5427-5433
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number34
DOIs
StatePublished - Dec 1 2006

Fingerprint

Glioma
Cognition
Neoplasms
Brain Neoplasms
Radiation
Pressure
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Brown, P. D., Jensen, A. W., Felten, S. J., Ballman, K. V., Schaefer, P. L., Jaeckle, K. A., ... Buckner, J. C. (2006). Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. Journal of Clinical Oncology, 24(34), 5427-5433. https://doi.org/10.1200/JCO.2006.08.5605
Brown, Paul D. ; Jensen, Ashley W. ; Felten, Sara J. ; Ballman, Karla V. ; Schaefer, Paul L. ; Jaeckle, Kurt A. ; Cerhan, Jane H. ; Buckner, Jan C. / Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 34. pp. 5427-5433.
@article{50e3a839c98a46aba61bb516041fcaac,
title = "Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma",
abstract = "Purpose: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed. Patients and Methods: We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time. Results: The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18{\%}, 16{\%}, 14{\%}, and 13{\%}, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression. Conclusion: The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.",
author = "Brown, {Paul D.} and Jensen, {Ashley W.} and Felten, {Sara J.} and Ballman, {Karla V.} and Schaefer, {Paul L.} and Jaeckle, {Kurt A.} and Cerhan, {Jane H.} and Buckner, {Jan C.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1200/JCO.2006.08.5605",
language = "English (US)",
volume = "24",
pages = "5427--5433",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "34",

}

Brown, PD, Jensen, AW, Felten, SJ, Ballman, KV, Schaefer, PL, Jaeckle, KA, Cerhan, JH & Buckner, JC 2006, 'Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma', Journal of Clinical Oncology, vol. 24, no. 34, pp. 5427-5433. https://doi.org/10.1200/JCO.2006.08.5605

Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. / Brown, Paul D.; Jensen, Ashley W.; Felten, Sara J.; Ballman, Karla V.; Schaefer, Paul L.; Jaeckle, Kurt A.; Cerhan, Jane H.; Buckner, Jan C.

In: Journal of Clinical Oncology, Vol. 24, No. 34, 01.12.2006, p. 5427-5433.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma

AU - Brown, Paul D.

AU - Jensen, Ashley W.

AU - Felten, Sara J.

AU - Ballman, Karla V.

AU - Schaefer, Paul L.

AU - Jaeckle, Kurt A.

AU - Cerhan, Jane H.

AU - Buckner, Jan C.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed. Patients and Methods: We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time. Results: The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression. Conclusion: The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.

AB - Purpose: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed. Patients and Methods: We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time. Results: The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression. Conclusion: The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.

UR - http://www.scopus.com/inward/record.url?scp=34247195502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247195502&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.5605

DO - 10.1200/JCO.2006.08.5605

M3 - Article

C2 - 17135644

AN - SCOPUS:34247195502

VL - 24

SP - 5427

EP - 5433

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 34

ER -